Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...
A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...
Chronic pain is a worldwide epidemic that disproportionately affects women. These surgeons have found innovative solutions - ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.
It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...
Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...
The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway out of the eye is too small, she explained. This could happen when glucose ...
As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...
7d
News Medical on MSNOpioid δ-receptor agonists show promise for treating IBS-like symptomsResearch reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...
16h
ZME Science on MSNOzempic Users Are Drinking Less Alcohol Without Even TryingIn a world where alcohol claims nearly 178,000 lives annually in the U.S. alone, a glimmer of hope has emerged from an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results